34 related articles for article (PubMed ID: 36434779)
1. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.
Valgimigli M; Costa F; Lokhnygina Y; Clare RM; Wallentin L; Moliterno DJ; Armstrong PW; White HD; Held C; Aylward PE; Van de Werf F; Harrington RA; Mahaffey KW; Tricoci P
Eur Heart J; 2017 Mar; 38(11):804-810. PubMed ID: 28363222
[TBL] [Abstract][Full Text] [Related]
2. Prasugrel and Ticagrelor Treatment Among Patients With ACS: Is There a Need for a New Randomized Trial?
Wöhrle J; Seeger J
JACC Cardiovasc Interv; 2022 Nov; 15(22):2281-2283. PubMed ID: 36423971
[No Abstract] [Full Text] [Related]
3. Temporal Trends of Bleeding Episodes during Half- vs. Standard-Dose Ticagrelor in Acute Coronary Syndrome Patients with Low Platelet Reactivity: A Randomized BLEEDING-ACS Trial.
Kim L; Choe JC; Ahn JH; Lee HW; Oh JH; Choi JH; Lee HC; Cha KS; Hong TJ; Jeong YH; Park JS
J Clin Med; 2021 Mar; 10(6):. PubMed ID: 33802015
[TBL] [Abstract][Full Text] [Related]
4. Factor XI inhibition in patients with acute coronary syndrome.
Raffo C; Capodanno D
Eur Heart J Suppl; 2024 Apr; 26(Suppl 1):i29-i34. PubMed ID: 38867863
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor Potentiates Cardioprotection by Remote Ischaemic Preconditioning: the Ticagrelor in Remote Ischaemic Preconditioning (TRIP) Randomized Clinical Trial.
Tsiafoutis I; Zografos T; Karelas D; Varelas P; Manousopoulos K; Nenekidis I; Koutouzis M; Lagadinos P; Koudounis P; Agelaki M; Katsanou K; Oikonomou E; Siasos G; Katsivas A
Hellenic J Cardiol; 2024 Jun; ():. PubMed ID: 38950885
[No Abstract] [Full Text] [Related]
6. Prasugrel dose de-escalation in diabetic patients with acute coronary syndrome receiving percutaneous coronary intervention: results from the HOST-REDUCE-POLYTECH-ACS trial.
Lee KS; Park KH; Park KW; Rha SW; Hwang D; Kang J; Han JK; Yang HM; Kang HJ; Koo BK; Lee NH; Rhew JY; Chun KJ; Lim YH; Bong JM; Bae JW; Lee BK; Kim SY; Shin WY; Lim HS; Park K; Kim HS
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):262-270. PubMed ID: 36715152
[TBL] [Abstract][Full Text] [Related]
7. Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes.
Koch T; Lahu S; Coughlan JJ; Cassese S; Voll F; Ndrepepa G; Menichelli M; Valina C; Hemetsberger R; Witzenbichler B; Bernlochner I; Joner M; Xhepa E; Mayer K; Kessler T; Laugwitz KL; Richardt G; Schunkert H; Angiolillo DJ; Sibbing D; Kastrati A; Kufner S
Thromb Haemost; 2023 Apr; 123(4):464-477. PubMed ID: 36442805
[TBL] [Abstract][Full Text] [Related]
8. Within and beyond 12-month efficacy and safety of antithrombotic strategies in patients with established coronary artery disease: two companion network meta-analyses of the 2022 joint clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), European Association for Acute CardioVascular Care (ACVC), and European Association of Preventive Cardiology (EAPC).
Navarese EP; Landi A; Oliva A; Piccolo R; Aboyans V; Angiolillo D; Atar D; Capodanno D; Fox KAA; Halvorsen S; James S; Jüni P; Kunadian V; Leonardi S; Mehran R; Montalescot G; Niebauer J; Price S; Storey RF; Völler H; Vranckx P; Windecker S; Valgimigli M
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):271-290. PubMed ID: 36869784
[TBL] [Abstract][Full Text] [Related]
9. Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial.
Spirito A; Kastrati A; Cao D; Baber U; Sartori S; Angiolillo DJ; Briguori C; Cohen DJ; Dangas G; Dudek D; Escaned J; Gibson CM; Zhang Z; Huber K; Kaul U; Kornowski R; Kunadian V; Han YL; Mehta SR; Sardella G; Sharma S; Shlofmitz RA; Vogel B; Collier T; Pocock S; Mehran R
Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):328-336. PubMed ID: 36649694
[TBL] [Abstract][Full Text] [Related]
10. Thrombogenicity and endothelial progenitor cells function during Acute myocardial infarction - comparison of Prasugrel versus Ticagrelor.
Wiessman M; Kheifets M; Schamroth Pravda N; Leshem Lev D; Ziv E; Kornowski R; Spectre G; Perl L
J Thromb Thrombolysis; 2023 Apr; 55(3):407-414. PubMed ID: 36598739
[TBL] [Abstract][Full Text] [Related]
11. Pre-admission antiplatelet therapy and treatment effect of ticagrelor vs. prasugrel in patients with acute coronary syndromes-a subgroup analysis of the ISAR-REACT 5 trial.
Lahu S; Ndrepepa G; Neumann FJ; Menichelli M; Bernlochner I; Richardt G; Wöhrle J; Witzenbichler B; Hemetsberger R; Mayer K; Akin I; Cassese S; Gewalt S; Xhepa E; Kufner S; Valina C; Sager HB; Joner M; Ibrahim T; Laugwitz KL; Schunkert H; Schüpke S; Kastrati A
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):687-694. PubMed ID: 35191982
[TBL] [Abstract][Full Text] [Related]
12. Head to head comparison of Prasugrel versus Ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials.
Bundhun PK; Shi JX; Huang F
BMC Pharmacol Toxicol; 2017 Dec; 18(1):80. PubMed ID: 29233189
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
[TBL] [Abstract][Full Text] [Related]
14. The effect of a Prasugrel- vs. a Ticagrelor-based strategy on total ischaemic and bleeding events in patients with acute coronary syndromes.
Aytekin A; Coughlan JJ; Ndrepepa G; Cassese S; Lahu S; Kufner S; Mayer K; Xhepa E; Gewalt S; Joner M; Hapfelmeier A; Angiolillo DJ; Menichelli M; Richardt G; Neumann FJ; Schunkert H; Kastrati A
Eur Heart J Cardiovasc Pharmacother; 2023 Apr; 9(3):231-239. PubMed ID: 36434779
[TBL] [Abstract][Full Text] [Related]
15. Prior Myocardial Infarction and Treatment Effect of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndromes - A Post-hoc Analysis of the ISAR-REACT 5 Trial.
Lahu S; Scalamogna M; Ndrepepa G; Menichelli M; Valina C; Hemetsberger R; Witzenbichler B; Bernlochner I; Joner M; Xhepa E; Hapfelmeier A; Kufner S; Sager HB; Mayer K; Kessler T; Laugwitz KL; Richardt G; Schunkert H; Neumann FJ; Kastrati A; Cassese S
J Am Heart Assoc; 2022 Dec; 11(24):e027257. PubMed ID: 36515247
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial.
Behnes M; Lahu S; Ndrepepa G; Menichelli M; Mayer K; Wöhrle J; Bernlochner I; Gewalt S; Witzenbichler B; Hochholzer W; Sibbing D; Cassese S; Angiolillo DJ; Hemetsberger R; Valina C; Müller A; Kufner S; Hamm CW; Xhepa E; Hapfelmeier A; Sager HB; Joner M; Fusaro M; Richardt G; Laugwitz KL; Neumann FJ; Schunkert H; Schüpke S; Kastrati A; Akin I
Clin Res Cardiol; 2023 Apr; 112(4):518-528. PubMed ID: 35789430
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
